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A role for intracellular ROS production has been recently implicated in the pathogenesis and progression of a wide variety of
neoplasias. ROS sources, such as NAD(P)H oxidase (Nox) complexes, are frequently activated in AML (acute myeloid leukemia)
blasts and strongly contribute to their proliferation, survival, and drug resistance. Myelodysplastic syndromes (MDS) comprise a
heterogeneous group of disorders characterized by ineffective hematopoiesis, with an increased propensity to develop AML. The
molecular basis forMDS progression is unknown, but a key element inMDS disease progression is the genomic instability. NADPH
oxidases are now recognized to have specific subcellular localizations, this targeting to specific compartments for localized ROS
production. Local Nox-dependent ROS production in the nucleusmay contribute to the regulation of redox-dependent cell growth,
differentiation, senescence, DNA damage, and apoptosis. We observed that Nox1, 2, and 4 isoforms and p22phox and Rac1 subunits
are expressed in MDS/AML cell lines and MDS samples, also in the nuclear fractions. Interestingly, Nox4 interacts with ERK and
Akt1 within nuclear speckle domain, suggesting that Nox4 could be involved in regulating gene expression and splicing factor
activity. These data contribute to the elucidation of the molecular mechanisms used by nuclear ROS to drive MDS evolution to
AML.
1. Introduction
The progression of a premalignant condition to a lethal
malignancy is thought to involve an accumulation of muta-
tions in genes that regulate cellular proliferation, survival,
and differentiation [1, 2]. The myelodysplastic syndromes
(MDSs) can be considered as a representative premalignant
hematopoietic disorder that can transform to acute myeloid
leukemia (AML) [3].
(Da Watson) MDS comprises a group of anemic disor-
ders of uncertain etiology characterized by abnormal cell
morphology in the bone marrow (BM) and peripheral blood
cytopenias [4]. According to the International Prognostic
Scoring System, the patients with MDS can be divided into
4 prognostic categories: low, intermediate I, intermediate II,
and high risk [5]. In about one-third of the patients with
MDS, the disease transforms into AML, within months to
a few years. These patients usually have a high risk disease,
including Int II or high-risk MDS [6]. The causative agent(s)
for these secondary events is poorly understood. The excess
ROS are known to be a genotoxic stress that can induce DNA
damage and mutation following ineffective repair of DNA
damage [7–10]. Increased levels of ROS have been detected in
bothAML and chronicmyeloid leukemia [11, 12].With regard
to MDS and oxidative stress, several studies have reported
that increased levels of ROS or oxidative DNA damage could
be detected in hematopoietic cells fromMDSpatients [13–15].
It has been demonstrated that RAS mutations in mye-
lodysplastic syndromes/myeloproliferative diseases result in
ROS production [16]. Moreover, another player of inositide
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signaling; that is, phosphatidylinositol 3 kinase (PI3K) has
been suggested to be involved, via its substrate Akt, in the
survival of MDS blasts [17].
NAD(P)H oxidase complexes, as ROS sources, are fre-
quently activated in AML blasts and strongly contribute
to proliferation, survival, and drug resistance of these cells
[18–20]. In leukemia cells, ROS generated by Nox4, at
least in part, transmit survival signals through the Akt-
PI3K pathway while their depletion leads to apoptosis [21].
Furthermore, NADPH oxidases are now recognized to have
specific subcellular localizations, thus being required for
localized ROS production [22]. Various ROS-generating and
ROS-degrading systems seem to play an important role in
different compartments of the cell.The nucleus itself contains
a number of proteins with oxidizable thiols that are essential
for transcription, chromatin stability, nuclear protein import
and export, and DNA replication and repair [23].
Kuroda et al. demonstrated that the endogenous Nox4
preferentially localizes to the nucleus in human endothelial
cells [24]. Thus, local Nox4-dependent ROS production in
the nucleus may contribute to regulation of redox-dependent
transcription factor and gene expression involved in cell
growth, differentiation, senescence, and apoptosis. In fact,
many transcription factors, includingAP-1, NF-𝜅B,Nrf2, p53,
glucocorticoid receptor, and nuclear kinases, such as PKC
(Protein kinase C), Akt, ERK2, and PKA (Protein kinase A),
are redox sensitive [22, 25].
In spite of these striking observations, most ROS nuclear
substrates have so far remained elusive, as well as nuclear
Nox4-derived ROS functions. Therefore, the first aim of this
study is to determine if Nox4 isoform is present in the nucleus
of MDS cells and the specific localization area of Nox4
complex. We therefore used the human cell line MOLM-
13, established from AML secondary to myelodysplastic
syndrome and the AML cell line THP1 and/or human blasts
obtained from patients with MDS. The broad object of this
research is to elucidate the role of nuclearNox-derivedROS in
myelodysplastic syndromes. Therefore, Nox4 expression has
been down-regulated and ROS decrease in the nucleus has
been checked in order to confirm the nuclear localization and
activity of NADPH oxidase.
Then, we searched for binding partners in the nucleus, in
particular signaling key molecules. To reveal the interactome
proteins that reside in nuclear Nox complex in human
MDS/AML cell line, coimmunoprecipitation assay has been
performed in order to check Nox interactions with nuclear
signaling players. Identification of substrates or binding
partners of nuclear NAD(P)H oxidases will pave the way to
finding new pharmacological treatments.
The data resulting from the present study could con-
tribute to shedding the light on the molecular mechanisms
used by this key intracellular pathway to driveMDS evolution
to AML and, in general, in hematological dysfunctions.
2. Materials and Methods
2.1. Patient Characteristics. Peripheral blood samples
(PBMCs) came from 10 MDS patients and 3 healthy normal
volunteers who had given informed consent according to
the Declaration of Helsinki. The samples came from the
Department of Hematology and Medical Oncology (L. e A.
Seràgnoli) of the Policlinico S. Orsola, Bologna, Italy. In all
of the subjects participating in this study, MDS diagnosis
was defined according to WHO classification [26]. For in
vitro experiments, PBMCs were isolated by Ficoll-Paque
(Amersham Biosciences, Sunnyvale, CA, USA) density-
gradient centrifugation, according to the manufacturer’s
protocol.
2.2. Cell Culture. The MDS cell line MOLM13 and the
AML cell line THP1 were purchased from DSMZ (German
Resource Centre for Biological Material). MOLM-13 cells
express FLT3-ITD and have been derived from the peripheral
blood of a patient with post-MDS AML [27, 28]. MOLM-13
carries internal tandem duplication of FLT3. THP1 is an acute
monocytic leukemia cell line.
Cell lines were cultured with 5% CO
2
at 37∘C in RPMI
(Mediatech, Inc., Herndon, VA) with 10% fetal calf serum
(FCS) and supplemented with 2mM L-glutamine, 100U/mL
penicillin, and 100 𝜇g/mL streptomycin (all from EuroClone
Spa, Italy).
2.3. Nox4 Silencing. Retroviral supernatants were produced
according toHuSH shRNAPlasmid Panels (29-mer)Applica-
tion Guide; AM12 cells were transfected with an empty vector
(pRS Vector, TR20003), a scrambled vector (HuSH 29-mer
non effective pRS vector, TR30012), and four NOX4 gene
specific shRNA expression pRS vectors (TI311637, TI311638,
TI311639, and TI311640) for 48 h. Retroviral supernatants
were then centrifuged at 2000×g for 5 minutes and used
for target cells (THP1) infection. Where indicated, cells were
infected with NOX4 shRNA retroviral vectors, empty vector,
or scrambled vector. Forty-eight hours after infection, cells
were exposed to 2 𝜇g/mL puromycin (Sigma Aldrich) for
24 hours, and subjected to evaluation of Nox4 expression
by Western blotting and confocal analysis and detection of
intracellular ROS levels.
2.4. Preparation of Cell Extracts. Cell extracts were obtained
as described by Maraldi et al. [29]. Briefly, cells were
extracted by addition of AT lysis buffer (20mM Tris-Cl, pH
7.0; 1% Nonidet P-40; 150mM NaCl; 10% glycerol; 10mM
EDTA; 20mMNaF; 5mM sodium pyrophosphate; and 1mM
Na3VO4) and freshly added SigmaAldrich Protease Inhibitor
Cocktail at 4∘C for 30min. Lysates were sonicated, cleared by
centrifugation, and immediately boiled in SDS sample buffer
or used for immunoprecipitation experiments, as described
below.
2.5. Nuclei Purification. Cell nuclei were purified as reported
by Cenni et al. [30]. Briefly, 400𝜇L of nuclear isolation
buffer (10mM Tris-HCl, pH 7.8, 1% Nonidet P-40, 10mM
𝛽-mercaptoethanol, 0.5mM phenylmethylsulfonyl fluoride,
1 𝜇g/mL aprotinin and leupeptin, and 5mM NaF) was added
to 5 × 106 cells for 8min on ice. MilliQ water (400𝜇L) was
then added to swell cells for 3min. Cells were sheared by
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passages through a 22-gauge needle. Nuclei were recovered
by centrifugation at 400×g at 4∘C for 6min and washed
once in 400𝜇L of washing buffer (10mM Tris-HCl, pH 7.4,
and 2mM MgCl
2
, plus inhibitors as described earlier in the
text). Supernatants (containing the cytosolic fractions) were
further centrifuged for 30min at 4000×g. Isolated nuclear
and cytoplasmic extracts were finally lysed in AT lysis buffer,
sonicated, and cleared by centrifugation.
2.6. Immunoprecipitation and Electrophoresis. Immunopre-
cipitation was performed as reported by Bertacchini et al.
[31]. For preclearing procedure nuclear lysateswere incubated
with 2 𝜇g anti-M2 for 1 hour (Sigma Aldrich) and then with
beads for additionally 30min, which were then removed
and discarded prior to the immunoprecipitation. Precleared
lysates, whose protein concentration was determined by the
Bradford method, were incubated 4 hours with 3 𝜇g of anti-
Nox4 (Novus Biologicals, CO, USA). Then samples were
treated with 30 𝜇L of 50% (v/v) of protein A/G agarose slurry
(GE Healthcare Biosciences, Uppsala, Sweden) at 4∘C with
gentle rocking for 1 h. Pellets were washed twice with 20mM
Tris-Cl, pH 7.0; 1%Nonidet P-40; 150mMNaCl; 10% glycerol;
10mM EDTA; 20mM NaF; 5mM sodium pyrophosphate,
once with 10mM Tris-Cl, pH 7.4, boiled in SDS sample
buffer, and centrifuged. Supernatants were loaded onto SDS-
polyacrylamide gel, blotted on Immobilon-P membranes
(Millipore, Waltham, MA, USA), and processed by Western
blot with the indicated antibodies.
2.7. Western Blot. The protocols of the Western blot were
performed as described by Hanson et al. [32]. Briefly, protein
extracts, quantified by a Bradford Protein Assay (Bio-Rad
Laboratories, CA, USA), underwent SDS-polyacrylamide
gel electrophoresis and were transferred to Immobilon-P
membranes. The following antibodies were used: rabbit anti-
ERK1/2, goat anti-Matrin3, goat anti-𝛽actin, anti-p22phox
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted
1 : 500, rabbit anti-Akt1, rabbit anti-Rac1, and rabbit anti-
ERK1/2 (Cell Signalling Technology, Beverly, MA, USA),
mouse anti-tubulin, rabbit anti-Nox1, and mouse anti-sc-
35 (Sigma Aldrich St. Louis, MO, USA), rabbit anti-Nox4
(Novus Biologicals, CO, USA), rabbit anti-Nox2, and mouse
anti-pH2A(Ser139) (Millipore, Billerica, MA, USA) diluted
1 : 1000; peroxidase-labelled anti-rabbit, mouse and goat
secondary antibodies diluted 1 : 3000 (Pierce Antibodies,
Thermo Scientific; Rockford, IL, USA). Ab dilution was per-
formed in TBS-T pH 7.6 containing 3% BSA.Themembranes
were visualized using Supersignal substrate chemilumines-
cence detection kit (Pierce, Rockford, IL, USA). Anti-𝛽actin
antibodywas used as control of protein loading.Quantization
of the signal was obtained by chemiluminescence detection
on aKodak Image Station 440CF and analysis with the Kodak
1D Image software.
2.8. Confocal Microscopy. Cells were fixed for 20min in 4%
ice-cold paraformaldehyde and then permeabilizedwith 0.1%
Triton X-100 in ice-cold phosphate-buffered saline (PBS) for
5min. Permeabilized samples were then blocked with 3%
of bovine serum albumin (BSA) in PBS for 30min at room
temperature and incubated with primary antibodies (Abs):
rabbit anti-Nox4 (Santa Cruz, CA, USA) (diluted 1 : 50),
mouse anti-sc-35 (Sigma Aldrich St. Louis, MO, USA) and
mouse anti pH2A (Ser139) (Millipore, Billerica, MA, USA)
(diluted 1 : 100), in PBS containing 3% BSA for 1 h at RT.
Secondary antibody was diluted 1 : 200 in PBS containing
3% BSA (goat anti-mouse Alexa 647 and goat anti-rabbit
Alexa 488). After washing in PBS, samples were stained with
1 𝜇g/mL DAPI in H
2
O for 1min and then mounted with
antifading medium (0.21M DABCO and 90% glycerol in
0.02M Tris, pH 8.0). Negative controls consisted of samples
not incubated with the primary antibody, but only with the
secondary antibody.
Confocal imaging was performed on a Nikon A1 confocal
laser scanning microscope as previously described [33].
Spectral analysis was carried out to exclude overlapping
between two signals or the influence of autofluorescence
background on the fluorochrome signals, as previously
shown [34]. The confocal serial sections were processed with
Image J software to obtain three-dimensional projections,
as previously described [35]. The image rendering was per-
formed by Adobe Photoshop software.
2.9. Nuclear ROS Imaging. Nuclear ROS were detected with





Emerald 1 (NucPE1) [36–39]. For all experiments, 5𝜇M solu-
tions of NucPE1 (from 5mM stocks in DMSO) were made in
PBS/glucose. The cells were then kept in an incubator (37∘C,
5% CO
2
) for a total of 30min in the dark. Fluorescence was
measured on a multiwell plate reader (Appliskan, Thermo
Scientific) using 488 nm filter for excitation and 535 nm filter
for emission.
Confocal fluorescence imaging studies were performed
with a Nikon A1 confocal laser scanning microscope. Excita-
tion ofNucPE1-loaded cells at 488 nmwas carried out with an
Ar laser and emission was collected at 535 nm. All images in
an experiment were collected simultaneously using identical
microscope settings. Image analysis was performed in Image
J.
2.10. Statistical Analysis. In vitro experiments were per-
formed in triplicate. For quantitative comparisons, values
were reported as mean ± SD based on triplicate analysis for
each sample. To test the significance of observed differences
between the study groups, unpaired Student’s t-test was
applied. A 𝑃 value <0.05 was considered to be statistically
significant.
3. Results
3.1. Patient Characteristics. Peripheral blood (PB) MCs from
10 patients affected byMDS (5 treated with azacitidine, 2 with
hydroxyurea, 1 with erythropoietin and 2with best supportive
care only) were examined. Median age was 70 years (range
65 to 82 years). MDS was diagnosed following World Health
Organization (WHO) classification [26]. Patient demograph-
ics and disease characteristics are summarized in Table 1.
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Table 1: Clinical, hematologic, and cytogenetic characteristics of
MDS patients.
WHO
diagnosis Karyotype Treatment Clinical outcome
RARS Normal Stable disease
RCMD del (7q) Diseaseprogression, death
RCMD del (20q) EPO AML
RAEB1 Normal 5-aza RAEB2
RAEB1 del (5q) Idrossiurea (HU) Stable disease
RAEB1 del (7q) Idrossiurea (HU) Stable disease
RAEB2 Tris (8) 5-aza AML, death
RAEB2 Tris (8) 5-aza AML, death
RAEB2 Normal 5-aza AML, death
AML Normal 5-aza AML, death
Karyotype analysis shows that different abnormalities are
present in the study group as well as different disease gravity
levels, as shown by WHO classification.
3.2. NADPH Oxidases Expression in MDS Samples and
MDS/AML Cell Lines. At first, we tested the expression level
of NADPH oxidase isoforms and their subunits by Western
blot (WB) analysis of total lysates of all the MDS collected
samples and of human MDS/AML cell lines (THP1 and
MOLM-13).
By using different kinds of affinity-purified antibodies
raised against distinct immunogens fromhumanNox1, Nox2,
Nox4, p22phox, and Rac1, we demonstrated that all these
proteins are present in MDS samples and humanMDS/AML
cell lines. Figure 1 shows the expression pattern of three
representative MDS samples compared to MOLM-13 and
THP1 cell lines and PBMC healthy donor. Nox1 and Nox4
isoforms seem to be highly expressed in all samples.
Interestingly, Nox4 is both expressed into the nucleus
and in the cytoplasm. In fact, confocal analysis (Figure 2(a))
demonstrated that in different MDS samples (images repre-
sentative of RAEB1, RAEB2, and RARS are shown) a punctate
staining of Nox4 is detectable inside the nuclei. Nox1 and
Nox2 signals show a cytoplasmic localization (not shown).
The same pattern has been observed also in MDS/AML cell
lines (Figure 2(b)).
In order to demonstrate the specificity of the immunoflu-
orescence signal, we performed Western blot analysis of
nuclear and cytoplasm subfractions (Figure 3). Also with this
approach we can see a high presence of Nox4 in nuclear
portions; moreover, the Nox4 subunit p22phox is present in
both the subfractions.
Rac, an important downstream effector of RAS, is an
activator of Nox2 and Nox4 and, in leukemic cells, Rac-1
and Akt activate Nox2 and Nox4 [20, 40]. RAS/Nox have
been also demonstrated to be modulators of cell growth
and proliferation via activating themitogen-activated protein
kinase ERK1/2 signaling pathway [41]. Beside Nox4 and its
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Figure 1: Expression of NADPH oxidases and their subunits.
Representative images of Western blot analysis of total lysates of
PBMC healthy donor (ctrl), MDS, MOLM-13, and THP1 samples
revealed with antibodies against NADPH oxidase isoforms 1, 2, and
4, Rac1, and p22phox subunits. 𝛽actin was used as loading internal
control.
ERK1/2 are also present in nuclear protein portions of both
MOLM-13 and THP1 cell lines (Figure 3).
3.3. Modulation of Nox-Derived Nuclear ROS Production. In
order to investigate the NADPH oxidase activity inside the





peroxy Emerald 1 (Figure 4). Confocal microscopy confirms
that there is a ROS production inside the nuclei (Figure 4(a)).
Even if the use of Nox4 synthetic inhibitor, diphenyl-
eneiodonium (DPI), is not directed to the nuclear part of
Nox4, as demonstrated by the fluorogenic probe assay, the
Nox4 activity inhibition reduces the nuclear ROS production
(Figures 4(a) and 4(b)).
A more selective approach, as Nox4 silencing, confirms
the Nox4 role in nuclear ROS production. The highest
downregulation of Nox4 was obtained with shRNA TI311638
and TI311640, as demonstrated byWestern blot (Figure 4(d)).
Immunofluorescence assay (Figure 4(c)) shows that the
decrease in Nox4 expression occurs both in cytoplasmic and
nuclear compartments. Overall, THP1 cells, treated with all
shRNA sequences, show a significant decrease in nuclear ROS
level.
3.4. Nuclear Nox4 Role. The production of ROS directly
inside the nuclei can be linked to DNA damage. In fact,
increasing evidence suggests that genetic changes in myeloid
malignancies lead to increased production of endogenous
sources of DNA damage, such as reactive oxygen species.
It has been shown recently that the phosphorylation level
of H2AX is crucial to determining whether cells will survive
after DNA damage [42].
Looking at nuclear H2A foci, as expected, we found that,
compared to healthy donor, MDS samples exhibit a huge
status of H2A phosphorylation (Figure 5), suggesting that
nNox4-generated ROS can induce nuclear DNA damage.
Then, we investigated the nuclear Nox4 binding network
(Figure 6). Based on the punctate Nox4 signal previously
observed (Figure 2), we tested whether this distribution






Figure 2: Immunofluorescence analysis of Nox4 expression. (a) Representative images at different magnifications showing superimposing
between DAPI (blue) and Nox4 (green) signals in three human MDS samples (from left to right RAEB1, RAEB2, and RARS first row and
RAEB1 and RAEB2 in the second row). (b) Representative images showing superimposing between DAPI (blue) and Nox4 (green) signals in
MOLM-13 and THP1 samples. Scale bar: 10𝜇m.
follows the localization of speckles nuclear domains by using
an antibody directed against sc-35. Sc-35 is involved in pre-
mRNA splicing and is found in the bodies in the nucleus
referred to as speckles, sc-35 domains, or splicing factor
compartments (SFCs). Figure 6(a) shows that the nuclear
signal of Nox4 (green) often colocalizes with the one of sc-
35 (red), generating an orange staining. The arrow indicates,
as example, the colocalization in MDS sample.
The interaction of Nox4 with sc-35 was confirmed also by
coimmunoprecipitation experiment (Figure 6(b)). Nuclear
extracts (NL) of THP1 were used for coimmunoprecipitation
analysis with anti-Nox4 (IPNox4), since this cell line express
the highest level of nuclear Nox4. Preclearing fraction,
obtained as described in method section, is shown as control
for nonspecific interactions with protein A/G: the only one
band is the one of IgG used in the preclearing step. This










Figure 3: Western blot analysis of cytosol (cyto) and nuclear
fractions (nuclei) of MOLM-13 and THP1 samples revealed with
anti-Nox4, anti-Akt1, anti-ERK1/2, anti-Rac1, and anti-p22phox.
Tubulin absence was used as index of nuclear extract’s purification.
Presented data are representative of three independent experiments.
experiment also confirms the interaction between Nox4 and
the subunit p22phox. Furthermore, Nox4 seems to be linked
with nuclear matrix protein, Matrin3, and with ERK1/2 and
Akt1, suggesting a direct role in nuclear MAPK and Akt
signaling regulation.
4. Discussion
Myelodysplastic syndromes refer to a heterogeneous group
of closely related hematological disorders that are character-
ized by an ineffective production of blood cells (dysplasia)
and a hypercellular or hypocellular marrow with impaired
morphology andmaturation (dysmyelopoiesis) [5]. Although
the genetic basis of MDS is not completely understood, a
significant percentage of MDS cases are characterized by
chromosomal aberrations [43, 44] and the transformation of
MDS to AML is often accompanied by additional mutations
[45]. Approximately, 30% myelodysplastic syndrome (MDS)
cases progress to acute myelogenous leukemia.
It is now well established that the progression of normal
cells to neoplastic transformation results from the accumula-
tion of mutations in genes that control cellular proliferation,
survival, and differentiation [1].
It has been proposed that AML requires a minimum of
two complementarymutations, one leading to enhanced pro-
liferation and the second leading to impaired differentiation
[46].
A significant percentage of MDS cases is characterized by
chromosomal deletions of 5q or 7q [3] and has previously
been reported to be high in a proportion of myeloid malig-
nancies [47, 48]. The next most frequent genetic alteration in
MDS is activating mutations of the RAS homologues occur-
ring in 20% of MDS patients reviewed in [49, 50]. Tumor
progression is accompanied by an increase in ROS, which
leads to an increased DNA damage. It is well established that
activation of oncogenes can lead to ROS production [51],
and ROS is an established source of endogenous double-
strand breaks [52]. Thus, acquisition of oncogenic changes
can initiate a cycle of genomic instability that has the potential
to create further mutations, which in turn may facilitate
leukemic disease progression. Several lines of evidence now
indicate that activation of RAS-mitogen-activated protein
(MAP) kinase pathways can generate increased ROS. In fact,
one candidate pathway for ROS production in MDS may
be signaling through RAC1 [53]. Another candidate pathway
for ROS production is signaling through extracellular signal-
regulated kinase 1/2 (ERK1/2).
It has been previously demonstrated that ERK phospho-
rylation occurred downstream from the Nox4 pathway, but
through the RAS activation in endoplasmic reticulum [54].
The presence and the activity in the nucleus of both PI3K/Akt
[55] and NAD(P)H oxidase isoform 4 have been described
[24]. Indeed, the altered expression ofNox4 could be involved
in a dysregulation of cell cycle and has also an important
meaning in high risk MDS patients. ROS can inactivate
nuclear-localized phosphatases and thereby enhance kinase
activation.Moreover, excessive production of ROS also could
lead to oxidative DNA damage.
In this point of view, the subcellular localization of Nox4
is likely to be especially important, given its constitutive
activity, unlike isoforms, such as Nox1 or Nox2, that require
agonist activation.
We observed in human MDS samples, showing DNA
damage sign and obtained from different disease grade
patients, that Nox4 isoform is, interestingly, localized into the
nucleus. Inhibition of Nox4 activity, obtained with DPI or
Nox4 silencing, induces a decline of nuclear ROS production,
confirming the activity of Nox4 within the nuclei.
Confocal and coimmunoprecipitation analysis demon-
strate Nox4 presences in speckle domains suggesting that
Nox4 could be involved in regulating DNA-mRNA process-
ing machinery by ROS production in specific nuclear area.
Also Matrin 3 has been demonstrated to bind DNA at sites
termed scaffold/matrix attachment regions to regulate gene
expression through interactions with chromatin remodel-
ing [56]. Here, we show that Nox4 coimmunoprecipitates
also with Matrin 3. Thus, Matrin 3 could be a docking
site where nuclear ROS signaling may exert its function
on transcription/pre-mRNA modulation in specific nuclear
domains.
Moreover, immunoprecipitation analysis demonstrated
that Nox4 interacts with Akt and ERK signaling, suggesting
a role in nuclear signaling dysregulation leading to MDS
progression. The identification of these binding partners of
nuclear Nox4 may pave the way to finding new pharmaco-
logical treatments.
Taken together, we suggest that nNox4 regulation may
have important pathophysiologic effects in MDS through
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Figure 4: Effect of Nox4 inhibition on nuclear ROS production. (a) Representative images showing staining with nuclear ROS probe (nuclear
peroxy Emerald 1) of THP1 in the presence or absence of 2 𝜇M DPI for 18 hours. Scale bar: 10 𝜇m. (b) Graph representing fluorescence
intensity of nuclear ROS probe (Nuclear peroxy Emerald 1) of MOLM-13 and THP1 in the presence or absence of 2𝜇M DPI for 18 hours.
(c) Representative images showing: superimposing between DAPI (blue) and Nox4 SC (green) signals of THP1 treated with empty vector
(EV) or Nox4-directed siRNA (38 and 40) as reported in Section 2. Scale bar: 10 𝜇m. (d) Representative images of Western blot analysis of
Nox4 silencing in THP1 cells. 𝛽actin was used as loading internal control. (e) Graph representing fluorescence intensity of nuclear ROS probe
(Nuclear peroxy Emerald 1) of THP1 treated with empty vector (EV), scrambled siRNA (SCR), or Nox4-directed siRNA (37, 38, 39, and 40).
Presented data are representative of three independent experiments. ∗𝑃 < 0.05 and ∗∗∗𝑃 < 0.001 versus Control.








Figure 5: DNA damage in MDS samples. (a) Representative images showing staining with anti-PH2A (red), as marker of DNA damage, in
three human MDS samples. Scale bar: 10 𝜇m. (b) Western blot analysis of total lysates of MDS samples revealed with anti-PH2A. 𝛽actin was
used as loading internal control.
modulation of nuclear signaling and DNA damage. For
example, Nox4 can be a critical mediator in oncogenic RAS-
induced DNA-damage response.
In addition to antioxidant therapy, targeted therapy for
STAT, RAS, and PI3K pathways, such as RAC1 [16], may be
amenable to inhibition of nuclear ROS sources and genomic
instability using small molecule inhibitors.
These therapeutic options are likely to represent impor-
tant treatments in MDS/AML. Nevertheless, efficacy of ROS
reduction on the reversal of genomic instability and disease
progression may rely on elucidation of the major routes
for ROS overproduction in cancer with multiple genetic
alterations.
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(red) signals in MDS, MOLM-13, and THP1 cells. Scale bar: 10 𝜇m. (b) Representative images of Western blot analysis of nuclear lysate
(NL), preclearing (preclear) sample obtained, as described in methods section, before immunoprecipitation experiment with Nox4 antibody
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All presented data are representative of three independent experiments.
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